The investigators aim to perform a randomized clinical trial to determine the optimal timing of hepatitis B vaccination after hematopoietic cell transplantation (HCT) through evaluating the immunity effect of two different vaccination schedules (initiated at 3 or 6 months after transplantation) in patients with different immune reconstitution status.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
1,500
Three doses of hepatitis B vaccine
Institute of Hematology & Blood Diseases Hospital
Tianjin, Tianjin Municipality, China
Titer of hepatitis B surface antibodies (HBsAb).
The investigators will compare the titer of HBsAb one month after the completion of 3 doses of hepatitis B vaccine in transplants with different timing of hepatitis B vaccination, different donor type and different immune reconstitution status.
Time frame: One month after the completion of 3 doses of hepatitis B vaccine.
HBV infection
HBV-DNA or HBsAg are positive
Time frame: Through study completion, an average of 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.